Skip to main content
Erschienen in: Endocrine 2/2017

18.10.2016 | Original Article

Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism

verfasst von: Cristiana Cipriani, Alice Abraham, Barbara C. Silva, Natalie E. Cusano, Mishaela R. Rubin, Donald J. McMahon, Chengchen Zhang, Didier Hans, Shonni J. Silverberg, John P. Bilezikian

Erschienen in: Endocrine | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Restoration of the euparathyroid state is associated with improvement of bone dynamics both in hypoparathyroidism and primary hyperparathyroidism. To date, no study has directly compared these two groups following correction of parathyroid hormone excess or deficiency. The study was designed to investigate changes in bone mineral density and trabecular bone score with restoration of the euparathyroid state by parathyroidectomy in primary hyperparathyroidism or recombinant parathyroid hormone [rhPTH(1-84)] replacement in hypoparathyroidism. This was a 2-year prospective intervention study in which we evaluated areal bone mineral density by DXA and trabecular bone score in 52 hypoparathyroid patients on rhPTH(1-84) replacement and 27 patients with primary hyperparathyroidism who underwent parathyroidectomy. We evaluated changes in areal bone mineral density by DXA and trabecular bone score at baseline, 6, 12, 18, and 24 months. After parathyroidectomy, areal bone mineral density increased from baseline at the lumbar spine and total hip at 6 months and at the femoral neck at 12 months, while there were no changes at the distal 1/3 radius. Treatment with rhPTH(1-84) was associated with significant increases in lumbar spine and decreases in distal 1/3 radius areal bone mineral density by 18 months in hypoparathyroid patients. At this time point, hypoparathyroid subjects demonstrated a significant increase in trabecular bone score from baseline, while there were no significant changes in trabecular bone score following parathyroidectomy. Bone mineral density increases both with administration of parathyroid hormone in a state of parathyroid hormone deficiency or removal of parathyroid hormone in a state of parathyroid hormone excess. However, only hypoparathyroid patients on rhPTH(1-84) appeared to have improvements in micro-architectural pattern as assessed by trabecular bone score.
Literatur
1.
Zurück zum Zitat B.C. Silva, A.G. Costa, N.E. Cusano, S. Kousteni, J.P. Bilezikian, Catabolic and anabolic actions of parathyroid hormone on the skeleton. J. Endocrinol. Invest. 34, 801–810 (2011)PubMedPubMedCentral B.C. Silva, A.G. Costa, N.E. Cusano, S. Kousteni, J.P. Bilezikian, Catabolic and anabolic actions of parathyroid hormone on the skeleton. J. Endocrinol. Invest. 34, 801–810 (2011)PubMedPubMedCentral
2.
Zurück zum Zitat S.J. Silverberg, E. Shane, L. de la Cruz, D.W. Dempster, F. Feldman, D. Seldin, T.P. Jacobs, E.S. Siris, M. Cafferty, M.V. Parisien, R. Lindsay, T.L. Clemens, J.P. Bilezikian, Skeletal disease in primary hyperparathyroidism. J. Bone Miner. Res. 4, 283–291 (1989)CrossRefPubMed S.J. Silverberg, E. Shane, L. de la Cruz, D.W. Dempster, F. Feldman, D. Seldin, T.P. Jacobs, E.S. Siris, M. Cafferty, M.V. Parisien, R. Lindsay, T.L. Clemens, J.P. Bilezikian, Skeletal disease in primary hyperparathyroidism. J. Bone Miner. Res. 4, 283–291 (1989)CrossRefPubMed
3.
Zurück zum Zitat D.W. Dempster, R. Muller, H. Zhou, T. Kohler, E. Shane, M. Parisien, S.J. Silverberg, J.P. Bilezikian, Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 41, 19–24 (2007)CrossRefPubMedPubMedCentral D.W. Dempster, R. Muller, H. Zhou, T. Kohler, E. Shane, M. Parisien, S.J. Silverberg, J.P. Bilezikian, Preserved three-dimensional cancellous bone structure in mild primary hyperparathyroidism. Bone 41, 19–24 (2007)CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat B.L. Langdahl, L. Mortensen, A. Vesterby, E.F. Eriksen, P. Charles, Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 18, 103–108 (1996)CrossRefPubMed B.L. Langdahl, L. Mortensen, A. Vesterby, E.F. Eriksen, P. Charles, Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone. 18, 103–108 (1996)CrossRefPubMed
5.
Zurück zum Zitat M.R. Rubin, D.W. Dempster, H. Zhou, E. Shane, T. Nickolas, J. Sliney Jr., S.J. Silverberg, J.P. Bilezikian, Dynamic and structural properties of the skeleton in hypoparathyroidism. J. Bone Miner. Res. 23, 2018–2024 (2008)CrossRefPubMedPubMedCentral M.R. Rubin, D.W. Dempster, H. Zhou, E. Shane, T. Nickolas, J. Sliney Jr., S.J. Silverberg, J.P. Bilezikian, Dynamic and structural properties of the skeleton in hypoparathyroidism. J. Bone Miner. Res. 23, 2018–2024 (2008)CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat N.E. Cusano, K.K. Nishiyama, C. Zhang, M.R. Rubin, S. Boutroy, D.J. McMahon, X.E. Guo, J.P. Bilezikian, Non-invasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J. Bone Miner. Res. (2015). doi:10.1002/jbmr.2609 N.E. Cusano, K.K. Nishiyama, C. Zhang, M.R. Rubin, S. Boutroy, D.J. McMahon, X.E. Guo, J.P. Bilezikian, Non-invasive assessment of skeletal microstructure and estimated bone strength in hypoparathyroidism. J. Bone Miner. Res. (2015). doi:10.​1002/​jbmr.​2609
7.
Zurück zum Zitat J.P. Bilezikian, A. Khan, J.T. Potts Jr., M.L. Brandi, B.L. Clarke, D. Shoback, H. Jüppner, P. D’Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26, 2317–2337 (2011)CrossRefPubMedPubMedCentral J.P. Bilezikian, A. Khan, J.T. Potts Jr., M.L. Brandi, B.L. Clarke, D. Shoback, H. Jüppner, P. D’Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26, 2317–2337 (2011)CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat S. Khosla, L.J. Melton 3rd, R.A. Wermers, C.S. Crowson, W. O’Fallon, B. Riggs, Primary hyperparathyroidism and the risk of fracture: a population-based study. J. Bone Miner. Res. 14, 1700–1707 (1999)CrossRefPubMed S. Khosla, L.J. Melton 3rd, R.A. Wermers, C.S. Crowson, W. O’Fallon, B. Riggs, Primary hyperparathyroidism and the risk of fracture: a population-based study. J. Bone Miner. Res. 14, 1700–1707 (1999)CrossRefPubMed
9.
Zurück zum Zitat E. Vignali, G. Viccica, D. Diacinti, F. Cetani, L. Cianferotti, E. Ambrogini et al., Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2306–2312 (2009)CrossRefPubMedPubMedCentral E. Vignali, G. Viccica, D. Diacinti, F. Cetani, L. Cianferotti, E. Ambrogini et al., Morphometric vertebral fractures in postmenopausal women with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 94, 2306–2312 (2009)CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat P. Vestergaard, L. Mosekilde, Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients. World J. Surg. 27, 343–349 (2003)CrossRefPubMed P. Vestergaard, L. Mosekilde, Fractures in patients with primary hyperparathyroidism: nationwide follow-up study of 1201 patients. World J. Surg. 27, 343–349 (2003)CrossRefPubMed
11.
Zurück zum Zitat N. Yu, P.T. Donnan, R.W. Flynn, M.J. Murphy, D. Smith, A. Rudman, G.P. Leese, Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin. Endocrinol. (Oxf.) 73, 30–34 (2010) N. Yu, P.T. Donnan, R.W. Flynn, M.J. Murphy, D. Smith, A. Rudman, G.P. Leese, Increased mortality and morbidity in mild primary hyperparathyroid patients. The Parathyroid Epidemiology and Audit Research Study (PEARS). Clin. Endocrinol. (Oxf.) 73, 30–34 (2010)
12.
Zurück zum Zitat J.P. Roux, J. Wegrzyn, S. Boutroy, M.L. Bouxsein, D. Hans, R. Chapurlat, The predictive value of trabecular bone score (TBS) on whole lumbar vertebrae mechanics: an ex vivo study. Osteoporos. Int. 24, 2455–2460 (2013)CrossRefPubMed J.P. Roux, J. Wegrzyn, S. Boutroy, M.L. Bouxsein, D. Hans, R. Chapurlat, The predictive value of trabecular bone score (TBS) on whole lumbar vertebrae mechanics: an ex vivo study. Osteoporos. Int. 24, 2455–2460 (2013)CrossRefPubMed
13.
Zurück zum Zitat C. Muschitz, R. Kocijan, J. Haschka, D. Pahr, A. Kaider, P. Pietschmann, D. Hans, G.K. Muschitz, A. Fahrleitner-Pammer, H. Resch, BS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79, 259–266 (2015)CrossRefPubMed C. Muschitz, R. Kocijan, J. Haschka, D. Pahr, A. Kaider, P. Pietschmann, D. Hans, G.K. Muschitz, A. Fahrleitner-Pammer, H. Resch, BS reflects trabecular microarchitecture in premenopausal women and men with idiopathic osteoporosis and low-traumatic fractures. Bone 79, 259–266 (2015)CrossRefPubMed
14.
Zurück zum Zitat S. Hansen, J.E. Beck Jensen, L. Rasmussen, E.M. Hauge, K. Brixen, Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT. J. Bone Miner. Res. 25, 1941–1947 (2010)CrossRefPubMed S. Hansen, J.E. Beck Jensen, L. Rasmussen, E.M. Hauge, K. Brixen, Effects on bone geometry, density, and microarchitecture in the distal radius but not the tibia in women with primary hyperparathyroidism: a case-control study using HR-pQCT. J. Bone Miner. Res. 25, 1941–1947 (2010)CrossRefPubMed
15.
Zurück zum Zitat B.C. Silva, S. Boutroy, C. Zhang, D.J. McMahon, B. Zhou, J. Wang, J. Udesky, S. Cremers, M. Sarquis, X.D. Guo, D. Hans, J.P. Bilezikian, Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 98, 1963–1970 (2013)CrossRefPubMedPubMedCentral B.C. Silva, S. Boutroy, C. Zhang, D.J. McMahon, B. Zhou, J. Wang, J. Udesky, S. Cremers, M. Sarquis, X.D. Guo, D. Hans, J.P. Bilezikian, Trabecular bone score (TBS)--a novel method to evaluate bone microarchitectural texture in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 98, 1963–1970 (2013)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat E.M. Stein, B.C. Silva, S. Boutroy, B. Zhou, J. Wang, J. Udesky, C. Zhang, D.J. McMahon, M. Romano, E. Dworakowski, A.G. Costa, N. Cusano, D. Irani, S. Cremers, E. Shane, X.E. Guo, J.P. Bilezikian, Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J. Bone Miner. Res. 28, 1029–1040 (2013)CrossRefPubMedPubMedCentral E.M. Stein, B.C. Silva, S. Boutroy, B. Zhou, J. Wang, J. Udesky, C. Zhang, D.J. McMahon, M. Romano, E. Dworakowski, A.G. Costa, N. Cusano, D. Irani, S. Cremers, E. Shane, X.E. Guo, J.P. Bilezikian, Primary hyperparathyroidism is associated with abnormal cortical and trabecular microstructure and reduced bone stiffness in postmenopausal women. J. Bone Miner. Res. 28, 1029–1040 (2013)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat S.J. Silverberg, E. Shane, T.P. Jacobs, E. Siris, J.P. Bilezikian, A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341, 1249–1255 (1999)CrossRefPubMed S.J. Silverberg, E. Shane, T.P. Jacobs, E. Siris, J.P. Bilezikian, A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341, 1249–1255 (1999)CrossRefPubMed
18.
Zurück zum Zitat M.R. Rubin, J.P. Bilezikian, D.J. McMahon, T. Jacobs, E. Shane, E. Siris, J. Udesky, S.J. Silverberg, The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J. Clin. Endocrinol. Metab. 93, 3462–3470 (2008)CrossRefPubMedPubMedCentral M.R. Rubin, J.P. Bilezikian, D.J. McMahon, T. Jacobs, E. Shane, E. Siris, J. Udesky, S.J. Silverberg, The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J. Clin. Endocrinol. Metab. 93, 3462–3470 (2008)CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat S.J. Silverberg, F. Gartenberg, T.P. Jacobs, E. Shane, E. Siris, R.B. Staron, D.J. McMahon, J.P. Bilezikian, Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 80, 729–734 (1995)PubMed S.J. Silverberg, F. Gartenberg, T.P. Jacobs, E. Shane, E. Siris, R.B. Staron, D.J. McMahon, J.P. Bilezikian, Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 80, 729–734 (1995)PubMed
20.
Zurück zum Zitat C. Eller-Vainicher, M. Filopanti, S. Palmieri, F.M. Ulivieri, V. Morelli, V.V. Zhukouskaya, E. Cairoli, R. Pino, A. Naccarato, U. Verga, A. Scillitani, P. Beck-Peccoz, I. Chiodini, Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 169, 155–162 (2013)CrossRefPubMed C. Eller-Vainicher, M. Filopanti, S. Palmieri, F.M. Ulivieri, V. Morelli, V.V. Zhukouskaya, E. Cairoli, R. Pino, A. Naccarato, U. Verga, A. Scillitani, P. Beck-Peccoz, I. Chiodini, Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur. J. Endocrinol. 169, 155–162 (2013)CrossRefPubMed
21.
Zurück zum Zitat L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections. J. Clin. Endocrinol. Metab. 29, 2504–2510 (2014) L. Underbjerg, T. Sikjaer, L. Mosekilde, L. Rejnmark, Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections. J. Clin. Endocrinol. Metab. 29, 2504–2510 (2014)
22.
Zurück zum Zitat M.L. Mendonça, F.A. Pereira, M.H. Nogueira-Barbosa, L.M. Monsignore, S.R. Teixeira, P.C. Watanabe, L.M. Maciel, F.J. de Paula, Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr. Disord. (2013). doi: 10.1186/1472-6823-13-1 M.L. Mendonça, F.A. Pereira, M.H. Nogueira-Barbosa, L.M. Monsignore, S.R. Teixeira, P.C. Watanabe, L.M. Maciel, F.J. de Paula, Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density. BMC Endocr. Disord. (2013). doi: 10.1186/1472-6823-13-1
23.
Zurück zum Zitat M.R. Rubin, D.W. Dempster, J. Sliney Jr., H. Zhou, T.L. Nickolas, E.M. Stein, E. Dworakowski, M. Dellabadia, R. Ives, D.J. McMahon, C. Zhang, S.J. Silverberg, E. Shane, S. Cremers, J.P. Bilezikian, PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J. Bone Miner. Res. 26, 2727–2736 (2011)CrossRefPubMedPubMedCentral M.R. Rubin, D.W. Dempster, J. Sliney Jr., H. Zhou, T.L. Nickolas, E.M. Stein, E. Dworakowski, M. Dellabadia, R. Ives, D.J. McMahon, C. Zhang, S.J. Silverberg, E. Shane, S. Cremers, J.P. Bilezikian, PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. J. Bone Miner. Res. 26, 2727–2736 (2011)CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat N.E. Cusano, M.R. Rubin, D.J. McMahon, C. Zhang, R. Ives, A. Tulley, J. Sliney Jr, S.C. Cremers, J.P. Bilezikian, Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J. Clin. Endocrinol. Metab. 98, 137–144 (2013)CrossRefPubMed N.E. Cusano, M.R. Rubin, D.J. McMahon, C. Zhang, R. Ives, A. Tulley, J. Sliney Jr, S.C. Cremers, J.P. Bilezikian, Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety. J. Clin. Endocrinol. Metab. 98, 137–144 (2013)CrossRefPubMed
25.
Zurück zum Zitat Y. Duan, V. De Luca, E. Seeman, Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J. Clin. Endocrinol. Metab. 84, 718–722 (1999)CrossRefPubMed Y. Duan, V. De Luca, E. Seeman, Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J. Clin. Endocrinol. Metab. 84, 718–722 (1999)CrossRefPubMed
26.
Zurück zum Zitat Q. Chen, H. Kaji, M.F. Iu, R. Nomura, H. Sowa, M. Yamauchi, T. Tsukamoto, T. Sugimoto, K. Chihara, Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J. Clin. Endocrinol. Metab. 88, 4655–4658 (2003)CrossRefPubMed Q. Chen, H. Kaji, M.F. Iu, R. Nomura, H. Sowa, M. Yamauchi, T. Tsukamoto, T. Sugimoto, K. Chihara, Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J. Clin. Endocrinol. Metab. 88, 4655–4658 (2003)CrossRefPubMed
27.
Zurück zum Zitat M.R. Rubin, J. Sliney Jr., D.J. McMahon, S.J. Silverberg, J.P. Bilezikian, Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos. Int. 21, 1927–1934 (2010)CrossRefPubMedPubMedCentral M.R. Rubin, J. Sliney Jr., D.J. McMahon, S.J. Silverberg, J.P. Bilezikian, Therapy of hypoparathyroidism with intact parathyroid hormone. Osteoporos. Int. 21, 1927–1934 (2010)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat N.E. Cusano, M.R. Rubin, D.J. McMahon, D. Irani, L. Anderson, E. Levy et al.. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J. Clin. Endocrinol. Metab. 99, 3694–3699 (2014)CrossRefPubMedPubMedCentral N.E. Cusano, M.R. Rubin, D.J. McMahon, D. Irani, L. Anderson, E. Levy et al.. PTH(1-84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J. Clin. Endocrinol. Metab. 99, 3694–3699 (2014)CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat J.P. Bilezikian, A.A. Khan, J.T. Potts Jr., Third International Workshop on the Management of Asymptomatic Primary H. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009)CrossRefPubMedPubMedCentral J.P. Bilezikian, A.A. Khan, J.T. Potts Jr., Third International Workshop on the Management of Asymptomatic Primary H. Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop. J. Clin. Endocrinol. Metab. 94, 335–339 (2009)CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat N.C. Harvey, C.C. Glüer, N. Binkley, E.V. McCloskey, M.L. Brandi, C. Cooper, D. Kendler, O. Lamy, A. Laslop, B.M. Camargos, J.Y. Reginster, R. Rizzoli, J.A. Kanis, Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78, 216–224 (2015)CrossRefPubMedPubMedCentral N.C. Harvey, C.C. Glüer, N. Binkley, E.V. McCloskey, M.L. Brandi, C. Cooper, D. Kendler, O. Lamy, A. Laslop, B.M. Camargos, J.Y. Reginster, R. Rizzoli, J.A. Kanis, Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone 78, 216–224 (2015)CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93, 3785–3793 (2008)CrossRefPubMed P.D. Miller, P.D. Delmas, R. Lindsay, N.B. Watts, M. Luckey, J. Adachi, K. Saag, S.L. Greenspan, E. Seeman, S. Boonen, S. Meeves, T.F. Lang, J.P. Bilezikian, Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J. Clin. Endocrinol. Metab. 93, 3785–3793 (2008)CrossRefPubMed
32.
Zurück zum Zitat R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–41 (2001)CrossRefPubMed R.M. Neer, C.D. Arnaud, J.R. Zanchetta, R. Prince, G.A. Gaich, J.Y. Reginster, A.B. Hodsman, E.F. Eriksen, S. Ish-Shalom, H.K. Genant, O. Wang, B.H. Mitlak, Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–41 (2001)CrossRefPubMed
33.
Zurück zum Zitat P. Christiansen, T. Steiniche, L. Mosekilde, I. Hessov, F. Melsen, Primary hyperparathyroidism: changes in trabecular bone remodeling following surgical treatment--evaluated by histomorphometric methods. Bone 11, 75–79 (1990)CrossRefPubMed P. Christiansen, T. Steiniche, L. Mosekilde, I. Hessov, F. Melsen, Primary hyperparathyroidism: changes in trabecular bone remodeling following surgical treatment--evaluated by histomorphometric methods. Bone 11, 75–79 (1990)CrossRefPubMed
34.
Zurück zum Zitat R.P. Heaney, The basis for the post-parathyroidectomy increase in bone mass. J. Bone Miner. Res. 17(Suppl 2), N154–157 (2002)PubMed R.P. Heaney, The basis for the post-parathyroidectomy increase in bone mass. J. Bone Miner. Res. 17(Suppl 2), N154–157 (2002)PubMed
35.
Zurück zum Zitat E. Romagnoli, C. Cipriani, I. Nofroni, C. Castro, M. Angelozzi, A. Scarpiello, J. Pepe, D. Diacinti, S. Piemonte, V. Carnevale, S. Minisola, Trabecular Bone Score (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 53, 154–159 (2013)CrossRefPubMed E. Romagnoli, C. Cipriani, I. Nofroni, C. Castro, M. Angelozzi, A. Scarpiello, J. Pepe, D. Diacinti, S. Piemonte, V. Carnevale, S. Minisola, Trabecular Bone Score (TBS): an indirect measure of bone micro-architecture in postmenopausal patients with primary hyperparathyroidism. Bone 53, 154–159 (2013)CrossRefPubMed
36.
Zurück zum Zitat C. Cipriani, B.C. Silva, N. Cusano, A. Costa, D. Irani, A. Abraham, D. McMahon, L.B. Anderson, E. Levy, M. Rubin, J.P. Bilezikian, Beneficial Effects of PTH(1-84) in Hypoparathyroidism as Determined by Trabecular Bone Score (TBS) 2014 ASBMR poste # SU0015 (2014) C. Cipriani, B.C. Silva, N. Cusano, A. Costa, D. Irani, A. Abraham, D. McMahon, L.B. Anderson, E. Levy, M. Rubin, J.P. Bilezikian, Beneficial Effects of PTH(1-84) in Hypoparathyroidism as Determined by Trabecular Bone Score (TBS) 2014 ASBMR poste # SU0015 (2014)
37.
Zurück zum Zitat S. Hansen, E.M. Hauge, L. Rasmussen, J.E. Jensen, K. Brixen, Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J. Bone Miner. Res. 27, 1150–1158 (2012)CrossRefPubMed S. Hansen, E.M. Hauge, L. Rasmussen, J.E. Jensen, K. Brixen, Parathyroidectomy improves bone geometry and microarchitecture in female patients with primary hyperparathyroidism: a one-year prospective controlled study using high-resolution peripheral quantitative computed tomography. J. Bone Miner. Res. 27, 1150–1158 (2012)CrossRefPubMed
38.
Zurück zum Zitat L. Rolighed, L. Rejnmark, T. Sikjaer, L. Heickendorff, P. Vestergaard, L. Mosekilde, P. Christiansen, Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 99, 1072–1080 (2014)CrossRefPubMed L. Rolighed, L. Rejnmark, T. Sikjaer, L. Heickendorff, P. Vestergaard, L. Mosekilde, P. Christiansen, Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial. J. Clin. Endocrinol. Metab. 99, 1072–1080 (2014)CrossRefPubMed
Metadaten
Titel
Skeletal changes after restoration of the euparathyroid state in patients with hypoparathyroidism and primary hyperparathyroidism
verfasst von
Cristiana Cipriani
Alice Abraham
Barbara C. Silva
Natalie E. Cusano
Mishaela R. Rubin
Donald J. McMahon
Chengchen Zhang
Didier Hans
Shonni J. Silverberg
John P. Bilezikian
Publikationsdatum
18.10.2016
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1101-8

Weitere Artikel der Ausgabe 2/2017

Endocrine 2/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Hereditäres Angioödem: Tablette könnte Akuttherapie erleichtern

05.06.2024 Hereditäres Angioödem Nachrichten

Medikamente zur Bedarfstherapie bei hereditärem Angioödem sind bisher nur als Injektionen und Infusionen verfügbar. Der Arzneistoff Sebetralstat kann oral verabreicht werden und liefert vielversprechende Daten.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.